| Serial Number | 79352298 |
| Word Mark | ODYSSION |
| Filing Date | Tuesday, May 24, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, February 6, 2024 |
| Registration Number | 7296103 |
| Registration Date | Tuesday, February 6, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 21, 2023 |
| Goods and Services | Pharmaceutical and veterinary preparations and substances for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations and substances for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; cells, cell lines, and cell cultures, all being cells for medical use, for use in the production of proteins for therapeutic use; reagents for medical use, namely, proteins being medical therapeutic reagents; therapeutic antibodies; vaccines |
| Goods and Services | Reagents for use in medical research and scientific research being biological analysis; proteins for use in the manufacture of pharmaceuticals and reagents; proteins in raw material form for use in medical research; cells, cell lines, and cell cultures, all being cells for clinical laboratory use, for use in the production of proteins for therapeutic use |
| Goods and Services | Scientific and technological services, namely, scientific research and design relating thereto in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; laboratory research services in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, scientific analysis and testing being measurement of substances in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; scientific analysis and measurement of molecules and characteristics in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research and medical development services in the field of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnological research, namely, biotechnology scientific testing, in the biotechnical, biomedical and pharmaceutical fields; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; pharmaceutical research and development for the pharmaceutical industry; research and development of vaccines and medicines; scientific research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; scientific research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing being product testing services; drug discovery services; product development, namely, drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; scientific research and development of molecules for therapeutic purposes; consultancy, advisory and information services in relation to all the aforesaid services |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 14, 2022 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 14, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 14, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | OMASS Therapeutics Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | OMASS Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | OMASS Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, October 13, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, October 14, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 18, 2022 | APPLICATION FILING RECEIPT MAILED |
| Monday, March 13, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, March 15, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, March 16, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, May 4, 2023 | REFUSAL PROCESSED BY MPU |
| Thursday, May 4, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, May 24, 2023 | REFUSAL PROCESSED BY IB |
| Wednesday, July 19, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, July 19, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, July 20, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, September 18, 2023 | ASSIGNED TO EXAMINER |
| Saturday, October 7, 2023 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Monday, October 16, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, October 16, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Monday, October 16, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, October 16, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Monday, October 16, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 1, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 21, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, November 1, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, November 1, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Tuesday, November 21, 2023 | NOTIFICATION PROCESSED BY IB |
| Tuesday, November 21, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 6, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, February 6, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Monday, May 6, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, May 10, 2024 | FINAL DISPOSITION NOTICE SENT TO IB |
| Sunday, June 2, 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, May 10, 2024 | FINAL DISPOSITION PROCESSED |